|
TIDMABC
RNS Number : 7567X
ABCAM Plc
21 February 2012
For immediate release 21 February 2012
ABCAM PLC
("Abcam" or "the Company")
Notification of Half Year Results
Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, will announce its interim results for the six months ended 31 December 2011 on Monday 12 March 2012.
A meeting for analysts will be held at 10am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated
Adviser
James Black - Corporate Broking
Buchanan + 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Notes for editors
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.
Abcam now has an online catalogue of over 86,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFFRFRIIFIF
| 
